<DOC>
	<DOCNO>NCT02585934</DOCNO>
	<brief_summary>This study seek confirm demonstrate treatment effect intepirdine ( RVT-101 ) adjunctive therapy donepezil treatment subject Alzheimer 's disease .</brief_summary>
	<brief_title>Study Evaluating Intepirdine ( RVT-101 ) Subjects With Mild Moderate Alzheimer 's Disease Donepezil : MINDSET Study</brief_title>
	<detailed_description>This Phase 3 study seek confirm demonstrate treatment effect intepirdine ( RVT-101 ) cognition activity daily live add stable donepezil treatment subject mild-to-moderate Alzheimer 's disease 24 week double-blind treatment . This study also provide information safety tolerability 35-mg dose intepirdine ( RVT-101 ) use combination donepezil compare donepezil alone . This study conduct agreement Special Protocol Assessment FDA . Subjects complete study eligible enroll 12 month open-label study RVT-101 ( RVT-101-3002 ) concomitant medication treatment Alzheimer 's disease include memantine allow .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Male female subject AD Ongoing donepezil therapy AD An MMSE score 12 24 inclusive Screening ; MMSE score 1026 inclusive Baseline Hachinski Ischaemia score less equal 4 Screening . If female , subject must : a. nonchildbearing potential surgically sterile ; , b. willing use adequate method birth control . Male subject sexually active also require use adequate form birth control . Subject ability comply procedure cognitive test opinion investigator . Subject reliable caregiver willing report subject 's status throughout study . Other Causes Dementia Diagnosis vascular dementia Atypical clinical feature clinical course dementia would lead investigator conclude symptom likely due alternate dementia diagnosis include , limited , frontotemporal dementia , Lewy body dementia , others . Confounding Medical Conditions History significant psychiatric illness schizophrenia bipolar affective disorder significant psychiatric illness opinion investigator would interfere participation study ; Any clinically relevant concomitant disease , , opinion investigator , make subject unsuitable inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>RVT-101</keyword>
	<keyword>donepezil</keyword>
	<keyword>intepirdine</keyword>
	<keyword>dementia</keyword>
</DOC>